Sosei subsidiary receives funding from NEDO

For project that aims to develop ophthalmic solutions

The Japanese New Energy and Industrial Technology Development Organisation (NEDO) is to fund the development of ophthalmic solutions by the Activus Pharma subsidiary of biopharmaceutical firm Sosei Group.

The grant is part of NEDO’s FY2011 Innovation Promotion Programme and will fund up to two-thirds of the development costs incurred in the project, which starts tomorrow (23 August) and runs to 28 February 2013.

Using Activus Pure Nano-particle Technology (APNT) and surface-modified nanoparticle technology, the firm aims to develop posterior eye segment medication.

Posterior eye segment diseases such as diabetic retinopathy and age-related maculopathy are the primary cause of blindness and other visual impairments in middle age.

Companies